Hoth Therapeutics Achieves Positive Preclinical Results for Potential Alzheimer’s Disease Treatment
Hoth Therapeutics (Nasdaq: HOTH) has reported positive results in a preclinical study evaluating HT-ALZ as a potential therapeutic for Alzheimer’s disease. The study showed that higher doses of HT-ALZ had positive effects on the cognitive function of animals.
The company’s share price almost doubled following the news.
Highlights
The results outpaced those achieved in a previous clinical study, demonstrating that the higher dose is the most beneficial in a spatial memory test performed at Washington University in St Louis.
Hoth has now completed the behavior results for Locomotor Activity/Exploratory Behavior, Elevated Plus Maze, Spatial Navigation Water Maze, Prepulse Inhibition of Startle, and Conditioned Fear.
The company will begin processing the brains of the animal subjects for total plaque load and soluble/insoluble beta amyloid levels, and will share further data as it becomes available.
About Hoth Therapeutics
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options.
